Figure 1).
Cumulative survival rate of patients receiving tenofovir disoproxil fumarate (± lamivudine) in combination with one year of hepatitis B immunoglobulin (n=24) to prevent recurrent hepatitis B post-liver transplantation (LT)
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.